Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

AIM: A first in human study to evaluate tolerability and pharmacokinetics followed by an early proof of mechanism (POM) study to determine whether the small orally, available molecule, Posiphen tartrate (Posiphen), lowers secreted (s) amyloid-β precursor protein (APP) α and -β, amyloid-β peptide (Aβ...

Descripción completa

Detalles Bibliográficos
Autores principales: Maccecchini, Maria L, Chang, Mee Young, Pan, Catherine, John, Varghese, Zetterberg, Henrik, Greig, Nigel H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Neurodegeneration
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415310/
https://www.ncbi.nlm.nih.gov/pubmed/22791904
http://dx.doi.org/10.1136/jnnp-2012-302589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415310/
https://www.ncbi.nlm.nih.gov/pubmed/22791904
http://dx.doi.org/10.1136/jnnp-2012-302589

Ejemplares similares